Feb 15, 2021 | Webinar

Epigenetic marker for the monitoring of bladder tumours

Watch the presentation of Dr. Fernando Lozano Palacio
(Barcelona, Spain)

During the virtual VI Symposium Liquid Biopsy, organised from 25 till 27 January 2021 by a scientific committee from the University Hospital of Santiago (Spain), Dr. Fernando Lozano Palacio from the University Hospital Vall d’Hebron (Barcelona, Spain) gave an interesting presentation about biomarkers in bladder cancer, entitled “Epigenetic marker for the monitoring of bladder tumours”.

Watch this presentation to learn more about:

The current follow-up of Non Muscle-Invasive Bladder Cancer (NMIBC) with some considerations and pitfalls
The discomfort of regular cystoscopies
The role of urinary markers in the follow-up of NMIBC

Download the free slide resource and brochure

Share this on your favourite network:

All updates

Other updates

The diagnostic value of urinary biomarkers in UTUC

Feb 2, 2024 | Publication

Reviewed by Mr. Hugh Mostafid (Royal Surrey County Hospital, Guildford, UK) UTUC: similarities and differences compared to bladder cancer While bladder tumours account for 90-95% of all urothelial carcinomas (UCa), only 5-10% of UCa cases involve the upper urinary...

Including Bladder EpiCheck® in NMIBC surveillance leads to a major reduction in healthcare costs

Jan 19, 2024 | Publication

Urinary biomarker tests, including Bladder EpiCheck®, are reimbursed from January 2024 in the Netherlands Reviewed by Prof. Joost Boormans (Erasmus MC Cancer Institute, Rotterdam, The Netherlands) Pitfalls of the current standard for NMIBC follow-up Due to the high...

Henry with intermediate-risk NMIBC finds follow-up cystoscopies burdensome. What now?

Jun 30, 2023 | Clinical case

Henry, 70 years old, used to work as a creative director in a chocolate factory. Once, he designed chocolates that looked like broccoli. Too bad, they were not favoured by the clients … He was initially diagnosed with a solitary small Ta low-grade (LG) tumour. He...

Privacy policy

Disclaimers

✉ info@bcamonitor.org